Mechanisms underlying the blood pressure-lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trial.

Diabetes Obes Metab · 2023 · PMC10087931 · PMID 36089810

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Hct numerically increased by 0.3 (95% CI ‐0.4; 1.1)% and 0.7 (95% CI 0.0; 1.5)% during empagliflozin and empagliflozin + losartan treatment, respectively, but this did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.